Clinical Trials Logo

Clinical Trial Summary

This is a open-label, randomized, paired design, multicenter study of the Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (R6000) for evaluating cardiovascular autonomic neuropathy. R6000 is novel intellectual diagnostic device for cardiovascular autonomic reflex tests and heart rate variability analysis. A total of 85 subjects will be enrolled in trial Ⅰ and 150 subjects will be enrolled in trial Ⅱ. In trial Ⅰ, subjects will be randomized to two groups, one of which will receive test by the tested device first and the other one will be tested by conventional blood pressure kit. The primary objective of this clinical trial is to evaluate the effectiveness of the Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System. The secondary objective is to evaluate the safety of the cardiovascular autonomic testing system and stability.


Clinical Trial Description

Trial I Tested device: Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (R6000). Control: Conventional blood pressure kit. Goal: To assess the consistency between the tested device and the conventional method in measuring blood pressure. Trial IIa Tested device: Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (R6000). Control: Ambulatory holter station. Goal: To assess the consistency between the tested device and the conventional devices in measuring heart rate variability (HRV). Trial IIb Tested device: Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (R6000). Control: Manual method with digital ECG machine, stethoscope and sphygmomanometer. Goal: To assess the consistency between the tested device and the manual method in determining cardiovascular autonomic neuropathy (CAN). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06447896
Study type Interventional
Source REEM (Shenzhen) Healthcare Co., Ltd
Contact
Status Completed
Phase N/A
Start date March 11, 2011
Completion date August 12, 2022

See also
  Status Clinical Trial Phase
Completed NCT00919347 - The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction N/A
Completed NCT02462616 - Risk Analysis for Cardiovascular Autonomic Neuropathy N/A
Completed NCT02461342 - Genetic, Environment and Its Interaction Analysis for Cardiovascular Autonomic Neuropathy N/A
Active, not recruiting NCT04625751 - Neurovascular Coupling and Autonomic Neuropathy in Type 2 Diabetes